CTLA4 and neoplasm: An outstanding study conducted by the Kenya Honda group reported that a consortium of 11 bacterial strains from healthy human donor feces could potentially induce IFN-γ-producing CD8+ T cells and enhance the therapeutic efficacy of immune checkpoint inhibitors (anti-PD-1 and anti-CTLA4 antibodies) in syngeneic tumor models (MC-38 tumor and melanoma) in a manner, dependent on CD103+ DCs and MHC-I molecules.